ARYX THERAPEUTICS, INC. Inactive Instrument
ARYx Therapeutics, Inc. Share Price Other OTC
Equities
ARYX
US0433871094
Biotechnology & Medical Research
| Sales 2008 | 19.72 1.65K | Sales 2009 | - | Capitalization | 88.66M 7.4B |
|---|---|---|---|---|---|
| Net income 2008 | -31M -2.59B | Net income 2009 | -33M -2.75B | EV / Sales 2008 | 40,19,605 x |
| Net cash position 2008 | 29.9 2.49K | Net Debt 2009 | 2.37 197.78 | EV / Sales 2009 | - |
| P/E ratio 2008 |
-1.76
x | P/E ratio 2009 |
-2.66
x | Employees | - |
| Yield 2008 * |
-
| Yield 2009 |
-
| Free-Float | 100% |
More Fundamentals
* Assessed data
More press releases
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
| 1st Jan change | Capi. | |
|---|---|---|
| -1.65% | 104B | |
| +6.75% | 97.47B | |
| +5.71% | 22.25B | |
| -12.60% | 21.68B | |
| -9.70% | 18.2B | |
| -39.98% | 17.02B | |
| -10.17% | 16.36B | |
| +6.12% | 14.39B | |
| +35.47% | 12.37B |
